Table 2 Univariate Cox proportional hazard analysis

From: Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients

Variable	Overall survival		Relapse-free survival
Variable	HR (95% Cl)	p	HR (95% Cl)	p
CA125	1 (1–1)	0.14	1 (1–1)	0.31
Stage		0.55		0.8
Stage I	1		1
Stage II	0.61 (0.12–3.14]	0.52	1.14 (0.4–3.19)	0.808
Stage III	2.99 (1.21–7.43]	0.018	2.64 (1.33–5.26)	0.006
Stage IV	5.35 (1.63–17.57)	0.006	4.84 (1.79–13.09)	0.002
Debulking		0.22		0.08
Debulking R0	1		1
Debulking R1	1.67 (0.73–3.8)	0.224	1.84 (0.92–3.67)	0.084
Debulking R2	2.17 (1.36–3.47)	0.001	2.76 (1.85–4.13)	< 0.0001
Age	1 (0.98–1)	0.73	1 (0.99–1)	0.48
CALR	0.96 (0.94–0.98)	< 0.0001	0.97 (0.95–0.98)	< 0.0001
DC-LAMP summary	0.86 (0.76–0.96)	0.0097	0.98 (0.94–1)	0.19
CD8 summary	1 (1–1)	0.011	1 (1–1)	0.057
CD20	0.2 (0.039–0.97)	0.046	0.5 (0.23–1.1)	0.087
NKp46	1 (0.82–1.2)	0.98	0.91 (0.73–1.1)	0.42

Back to article page